Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00900055|
Recruitment Status : Active, not recruiting
First Posted : May 12, 2009
Last Update Posted : January 10, 2018
RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers.
PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.
|Condition or disease||Intervention/treatment|
|Chronic Myeloproliferative Disorders Fanconi Anemia Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic/Myeloproliferative Neoplasms||Genetic: microarray analysis Genetic: polyacrylamide gel electrophoresis Genetic: polymerase chain reaction Genetic: protein expression analysis Genetic: reverse transcriptase-polymerase chain reaction Genetic: western blotting Other: chromatography Other: high performance liquid chromatography Other: immunoenzyme technique|
- Identify the specific molecular function of the Fanconi anemia (FA) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers.
- Identify functional defects in hematopoietic stromal cells, including macrophages, from patients with FA, and selected blood cancers as well as normal volunteers.
OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts are collected for loss-of-function and gain-of-function analysis related to the Fanconi anemia complementing gene.
|Study Type :||Observational|
|Actual Enrollment :||213 participants|
|Official Title:||Dysregulation of Hematopoiesis in Fanconi Anemia|
|Study Start Date :||June 1975|
|Estimated Primary Completion Date :||January 2020|
|Estimated Study Completion Date :||January 2020|
- Loss of function analyses [ Time Frame: Duration of the study ]
- Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells [ Time Frame: Duration of the study ]
- Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins [ Time Frame: Duration of the study ]
- Microsequencing of unique proteins [ Time Frame: Duration of the study ]
- Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein [ Time Frame: Duration of the study ]
- Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood [ Time Frame: Duration of the study ]
- Identification of functional defects in Fanconi anemia hematopoietic stromal cells [ Time Frame: Duration of the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900055
|United States, Oregon|
|Knight Cancer Institute at Oregon Health and Science University|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Grover C. Bagby, MD||OHSU Knight Cancer Institute|